![Tastytrade logo](https://www.finder.com/niche-builder/670957fd05517.png)
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
GlycoMimetics is a biotechnology business based in the US. GlycoMimetics shares (GLYC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.23 – a decrease of 2.05% over the previous week. GlycoMimetics employs 35 staff and has a trailing 12-month revenue of around $10,000.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $0.23 |
---|---|
52-week range | $0.14 - $3.53 |
50-day moving average | $0.29 |
200-day moving average | $0.72 |
Wall St. target price | $1.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2055 from 2024-12-19
1 week (2024-12-13) | -13.94% |
---|---|
1 month (2024-11-21) | -35.78% |
3 months (2024-09-20) | 24.70% |
6 months (2024-06-21) | -20.13% |
1 year (2023-12-21) | -90.35% |
---|---|
2 years (2022-12-21) | -90.66% |
3 years (2021-12-21) | 1.57 |
5 years (2019-12-20) | 5.5 |
Revenue TTM | $10,000 |
---|---|
Gross profit TTM | $75,000 |
Return on assets TTM | -59.25% |
Return on equity TTM | -104.49% |
Profit margin | 0% |
Book value | $0.60 |
Market Capitalization | $14.3 million |
TTM: trailing 12 months
We're not expecting GlycoMimetics to pay a dividend over the next 12 months.
Over the last 12 months, GlycoMimetics's shares have ranged in value from as little as $0.1406 up to $3.5299. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GlycoMimetics's is 1.842. This would suggest that GlycoMimetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
GlycoMimetics, Inc. , a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Our star ratings for online brokerages are based on how they stack up in nine key categories.
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Check out the best-performing ETFs so far in 2024.